Skip to main content

Table 1 Patient characteristics a

From: Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative

Characteristics

All (n= 65)

Pso (n= 38)

PsA (n= 27)

P-value

Age, yr

53 (41 to 61)

54 (41 to 65)

52 (41 to 59)

0.526

Males, n (%)

35 (54)

21 (55)

14 (52)

0.806

Psoriasis disease duration, yr

20 (9 to 32)

20 (8 to 35)

20 (10 to 31)

0.931

Body surface area score, mean (SD)

9.2 (16)

8.1 (13.7)

10.8 (19.0)

0.827

PASI score, mean (SD)

7.8 (9.3)

7.3 (7.9)

8.7 (11.2)

0.967

Psoriatic arthritis, n (%)

27 (41)

–

–

–

Psoriatic arthritis disease duration, yr

–

–

10 (4 to 15.5)

–

Tender joint count (0 to 68), mean (SD)

–

–

8.9 (10.8)

–

Swollen joint count (0 to 66), mean (SD)

–

–

5.4 (9.0)

–

ASAS inflammatory back pain criteria met, n (%)

–

–

4 (17)

–

Calin inflammatory back pain criteria met, n (%)

–

–

5 (21)

–

Enthesitis score (0 to 6), mean (SD)

–

–

1.0 (1.5)

–

Dactylitis count (0 to 20), mean (SD)

–

–

1.4 (3.8)

–

Sacroiliac disease diagnosed by CT, n (%)

–

–

12 (44)

–

DMARD therapy, n (%)

6 (9)

2 (5)

4 (15)

0.224

Biologic therapy, n (%)

25 (39)

10 (26)

15 (56)

0.022

DMARD and biologic therapy, n (%)

4 (6)

2 (5)

2 (7)

1.000

NSAID therapy, n (%)

15 (23)

3 (8)

12 (44)

0.001

Phototherapy, n (%)

3 (5)

1 (3)

2 (7)

0.565

Topical steroid therapy, n (%)

24 (37)

14 (37)

10 (37)

1.000

Systemic steroid therapy, n (%)

1 (2)

0 (0)

1 (4)

0.415

Diabetes mellitus, n (%)

7 (11)

4 (11)

3 (11)

1.000

Hypertension, n (%)

21 (32)

13 (34)

8 (30)

0.791

Dyslipidemia, n (%)

44 (68)

29 (76)

15 (56)

0.108

Current tobacco use, n (%)

6 (9)

3 (8)

3 (11)

1.000

Former tobacco use, n (%)

18 (28)

12 (32)

6 (22)

0.684

Pack-years tobacco use

0 (0 to 4.5)

0 (0 to 5)

0 (0 to 0.8)

0.590

Diabetes mellitus therapy, n (%)

4 (6)

2 (5)

2 (7)

1.000

Antihypertensive therapy, n (%)

12 (19)

7 (18)

5 (19)

1.000

Hyperlipidemia therapy, n (%)

24 (37)

15 (39)

9 (33)

0.795

Body mass index, kg/m 2

29 (25.9 to 32.3)

29 (24.9 to 32.4)

29 (26.7 to 32)

0.572

Systolic blood pressure, mmHg

125 (116 to 135)

129 (120 to 135)

122 (115 to 133)

0.266

Diastolic blood pressure, mmHg

72 (65 to 78)

71 (66 to 78)

74 (63 to 79)

0.719

Fasting blood glucose, mg/dl

94 (89 to 104)

94 (89 to 104)

94 (89 to 107)

0.895

Total cholesterol, mg/dl

184 (158 to 203)

185 (158 to 207)

172 (157 to 201)

0.910

Triglycerides, mg/dl

108 (84 to 137)

109 (84 to 149)

101 (81 to 131)

0.604

High-density lipoprotein cholesterol, mg/dl

52 (42 to 63)

52 (42 to 69)

51 (47 to 59)

0.947

Low-density lipoprotein cholesterol, mg/dl

96 (80 to 125)

95 (80 to 125)

98 (78 to 125)

0.851

Erythrocyte sedimentation rate, mm/hr

8 (5 to 13)

8 (4 to 10)

12 (5 to 18)

0.097

High-sensitivity C-reactive protein, g/dl

1.7 (0.7 to 4.2)

1.2 (0.7 to 3.1)

3.0 (0.8 to 8)

0.221

  1. aASAS, Assessment of SpondyloArthritis international Society; DMARD, Disease-modifying antirheumatic drug; IQR, Interquartile range; NSAID, Nonsteroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index; PsA, Psoriatic arthritis; Pso, Psoriasis. Data are reported as median (IQR) unless indicated otherwise. DMARD therapy denotes methotrexate use, except for 1 patient who was taking both methotrexate and hydroxychloroquine. Biologic therapy indicates active TNF antagonist or anti-IL-12/23 receptor use except for one patient who was treated with abatacept for psoriatic arthritis. Reported P-values are for comparisons of Pso vs. PsA using Fisher’s exact tests for categorical variables, Mann-Whitney U tests for non-normally distributed continuous variables, and Student’s t-tests for normally distributed continuous variables. P < 0.05 was set as the significance level.